BiotechTube

daptomycin (up to 14 days)

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Soft Tissue Infections

Conditions

Soft Tissue Infections

Trial Timeline

Jan 1, 2005 → Nov 1, 2006

NCT ID
NCT00102947

About daptomycin (up to 14 days)

daptomycin (up to 14 days) is a approved stage product being developed by Merck for Soft Tissue Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT00102947. Target conditions include Soft Tissue Infections.

What happened to similar drugs?

1 of 14 similar drugs in Soft Tissue Infections were approved

Approved (1) Terminated (2) Active (11)
✅linezolid + vancomycinPfizerApproved
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
❌Etoricoxib 60 mg + Etoricoxib 90 mgMerckPhase 3
🔄ridaforolimus + PlaceboMerckPhase 3
🔄Diclofenac sodiumNovartisPhase 3
🔄Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00102947ApprovedTerminated

Competing Products

20 competing products in Soft Tissue Infections

See all competitors
ProductCompanyStageHype Score
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
Eribulin mesylateEisaiPre-clinical
26
E7389EisaiPhase 2
35
eribulin mesylateEisaiPhase 2
35
Olaratumab + Gemcitabine + Docetaxel + PlaceboEli LillyPhase 1/2
32
LY573636-sodiumEli LillyPhase 2
35
OlaratumabEli LillyPre-clinical
26
Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
40
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + Pembrolizumab (KEYTRUDA®)Eli LillyPhase 1
29
Olaratumab + doxorubicinEli LillyPhase 1/2
32
TrabectedinJohnson & JohnsonPre-clinical
26
Doxorubicin + Trabectedin + DexamethasoneJohnson & JohnsonPhase 1
29
Apatinib Mesylate, doxorubicin, ifosfamideJiangsu Hengrui MedicinePhase 2
31
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
31
Durvalumab and Tremelimumab + DoxorubicinAstraZenecaPhase 2
35
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + OlaparibAstraZenecaPhase 2
35